STAXYN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7696206 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| US6362178 | BAYER HLTHCARE | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct, 2018
(5 years ago) | |
| US8613950 | BAYER HLTHCARE | Pharmaceutical forms with improved pharmacokinetic properties |
Dec, 2028
(4 years from now) | |
Staxyn is owned by Bayer Hlthcare.
Staxyn contains Vardenafil Hydrochloride.
Staxyn has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Staxyn are:
- US7696206
- US6362178
Staxyn was authorised for market use on 17 June, 2010.
Staxyn is available in tablet, orally disintegrating;oral dosage forms.
Staxyn can be used as treatment of erectile dysfunction.
The generics of Staxyn are possible to be released after 23 December, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2013 |
Drugs and Companies using
VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date:
17 June, 2010Treatment:
Treatment of erectile dysfunctionDosage:
TABLET, ORALLY DISINTEGRATING;ORAL
How can I launch a generic of STAXYN before its drug patent expiration?
More Information on Dosage
STAXYN family patents
